Regulatory status
Sermorelin is classified as an unapproved research compound. There is no FDA-approved label, indication, or dosing information for this substance in the data reviewed.
What sermorelin is
Sermorelin is studied in a research context as a growth hormone releasing hormone (GHRH) analogue. No approved drug label exists to define its official mechanism, class, or brand names.
Trial footprint
Sermorelin and related GHRH analogues have been the subject of 42 registered clinical trials. Sample registrations include a Phase 2 study of GHRH in elderly participants over a three month treatment period, which was terminated. Another trial examining a GHRH analogue in abdominal obesity and cardiovascular inflammation was withdrawn before enrollment. A separate observational study looked at somatropin treatment in children and reached completion, though it did not test sermorelin directly.
FAQ
No. Sermorelin does not currently have an FDA-approved label according to the data reviewed. It is classified as an unapproved research compound.
There are 42 registered clinical trials associated with sermorelin and related GHRH analogues. These include studies that were terminated, withdrawn, or completed, reflecting a mixed research record.
Sermorelin is studied as a growth hormone releasing hormone (GHRH) analogue in research settings. No approved label defines an official mechanism or indication for it.
Yes. A Phase 2 trial examining GHRH in elderly participants was terminated, and a separate trial on abdominal obesity and cardiovascular inflammation was withdrawn before it began.
No side effect report data was available in the dataset reviewed for sermorelin.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: ClinicalTrials.gov RxNorm
Updated 2026-09-19